Noble Capital Markets Served as Co-Placement Agents to Eledon Pharmaceuticals (ELDN) in $54mm Private Placement

May 30, 2024

Noble Capital Markets is pleased to announce its role as co-placement agent for Eledon Pharmaceuticals into a securities purchase agreement with certain institutional and accredited healthcare investors for a private investment in public equity financing that is expected to result in gross proceeds of approximately $50 million, before deducting offering expenses. Pursuant to the terms of the securities purchase agreement, Eledon is selling an aggregate of 13,110,484 shares of its common stock (“Common Stock”) at a price of $2.37 per share and pre-funded warrants at a price of $2.369 per underlying share, which are exercisable to purchase 7,989,516 shares of Common Stock at a price of $0.001 per share.

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. 

This transaction highlights Noble’s ongoing commitment to providing strategic capital markets and advisory services to middle-market companies across a wide range of sectors. With deep sector knowledge and a client-first approach, Noble supports companies throughout their lifecycle — from capital formation to M&A execution.

For more information on Noble’s investment banking services, click here

For more information on this transaction, contact Nathan Cali @ ncali@noblecapitalmarkets.com